Company Profile
Insulet Corporation is a US-based manufacturer of tubeless wearable insulin delivery systems, headquartered in Acton, Massachusetts, USA. Founded in 2000, the company operates as a publicly listed entity on the Nasdaq Stock Exchange (PODD) with approximately 5,400 employees, serving global diabetes management markets across 19 countries with a focus on simplifying insulin therapy for Type 1 and Type 2 diabetes patients.
Core Products ＆ Technologies
Omnipod Insulin Management System
• Omnipod 5: FDA-cleared automated insulin delivery (AID) system integrating a tubeless disposable Pod with compatible continuous glucose monitors (CGM) for closed-loop glucose management; algorithm update approved December 2025 with enhanced automation and new 100 mg/dL target
• Omnipod DASH: Bluetooth-enabled tubeless insulin pump controlled via handheld Personal Diabetes Manager (PDM) or smartphone app
• Omnipod GO: Simplified basal-only insulin delivery system for Type 2 diabetes patients requiring long-acting insulin
• Omnipod Pod: Waterproof, tubeless, wearable disposable insulin reservoir delivering up to 72 hours of continuous subcutaneous insulin infusion
Digital Health ＆ Connectivity
• Omnipod 5 App: Smartphone control application enabling insulin management, glucose monitoring integration, and caregiver remote access
• FreeStyle Libre 3 Plus Integration: Completed U.S. limited market release of Omnipod 5 algorithm with FreeStyle Libre 3 Plus CGM connectivity (2026)
• Omnipod Discover: Digital education and onboarding platform for new Omnipod users
Market Position ＆ Certifications
Insulet holds a global leadership position in the tubeless insulin pump and automated insulin delivery market, competing with Medtronic (MiniMed 780G), Tandem Diabetes Care (t:slim X2 with Control-IQ), and Ypsomed (YpsoPump). Key strengths include:
• 26 years of US diabetes technology innovation heritage since founding
• Tubeless differentiation: Only major AID platform with a fully disposable, tubeless, waterproof wearable Pod design
• Regulatory compliance: FDA 510(k) cleared for Omnipod 5 and algorithm enhancements; CE marked for European markets; approved in Canada, Middle East, and Australia
• Pharmacy channel access: Unique insulin pump available through retail pharmacy distribution, lowering barriers to therapy initiation
• Manufacturing scale: Highly automated production facilities in Malaysia supporting global demand and margin expansion
Corporate Timeline
2000 — Founded in Acton, Massachusetts, USA, to develop tubeless insulin delivery
2007 — Completed initial public offering on Nasdaq
2018 — Launched Omnipod DASH, the first Bluetooth-enabled tubeless insulin pump
2022 — Launched Omnipod 5 AID system in the U.S., integrating with Dexcom G6 CGM
2024 — Full-year revenue surpassed $2 billion; launched Omnipod GO for Type 2 diabetes
2025 — Full-year revenue reached $2.71 billion (+31%); Omnipod 5 algorithm enhancements received FDA 510(k) clearance (December); board approved $350M share repurchase authorization
2026 — Q1 revenue $761.7M (+34% YoY); launched Omnipod 5 in five Middle East countries (February); completed limited market release of updated algorithm with FreeStyle Libre 3 Plus integration (May); enrolled first participant in EVOLVE pivotal study for Type 2 diabetes fully closed-loop system (May); issued voluntary medical device correction for certain Omnipod 5 lots (March)
Target Markets ＆ Applications
• Type 1 Diabetes AID: Omnipod 5 for automated insulin delivery with CGM integration, eliminating multiple daily injections and fingerstick glucose checks
• Type 2 Diabetes Insulin Therapy: Omnipod GO for basal insulin delivery and Omnipod 5 for intensive insulin management in insulin-requiring Type 2 patients
• Pediatric Diabetes: Omnipod 5 approved for ages 2+ in the U.S., offering tubeless freedom for children and adolescents
• International Expansion: Omnipod 5 and Discover platform rolling out across Europe, Canada, Middle East, and Australia
Contact Information
Global Headquarters
Address: 600 Technology Park Drive, Suite 200, Acton, MA 01720, USA
Telephone: +1 978 600 6300
Website: insulet.com
Corporate Status
Entity Type: Publicly Listed Company (No Parent Company)
Stock: Nasdaq: PODD
Investor Relations: investor.insulet.com
